Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer

Figure 3

Progression-free survival and overall survival. (a) Median PFS or MST of all 34 patients. (b) PFS of the PPV patients combined with or without PKM. (c) PFS of the PPV patients combined with or without chemotherapy. (d) MST of the PPV patients combined with or without PKM. (e) MST of the PPV patients combined with or without chemotherapy.

(a)

(b)

(c)

(d)

(e)